AU6784400A - Treatment of metastatic disease - Google Patents

Treatment of metastatic disease Download PDF

Info

Publication number
AU6784400A
AU6784400A AU67844/00A AU6784400A AU6784400A AU 6784400 A AU6784400 A AU 6784400A AU 67844/00 A AU67844/00 A AU 67844/00A AU 6784400 A AU6784400 A AU 6784400A AU 6784400 A AU6784400 A AU 6784400A
Authority
AU
Australia
Prior art keywords
epha2
cells
antibody
metastatic
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU67844/00A
Other languages
English (en)
Inventor
Patrick W. Hein
Katherine E. Kilpatrick
Michael Scott Kinch
Nicole D. Zantec
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
University of North Carolina at Chapel Hill
Purdue Research Foundation
Original Assignee
Glaxo Group Ltd
University of North Carolina at Chapel Hill
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22529456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU6784400(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd, University of North Carolina at Chapel Hill, Purdue Research Foundation filed Critical Glaxo Group Ltd
Publication of AU6784400A publication Critical patent/AU6784400A/en
Priority to AU2006202023A priority Critical patent/AU2006202023B2/en
Priority to AU2008264177A priority patent/AU2008264177A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU67844/00A 1999-08-17 2000-08-17 Treatment of metastatic disease Abandoned AU6784400A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2006202023A AU2006202023B2 (en) 1999-08-17 2006-05-12 Treatment of metastatic disease
AU2008264177A AU2008264177A1 (en) 1999-08-17 2008-12-24 Treatment of metastatic disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14925899P 1999-08-17 1999-08-17
US60149258 1999-08-17
PCT/US2000/022670 WO2001012172A1 (en) 1999-08-17 2000-08-17 Treatment of metastatic disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006202023A Division AU2006202023B2 (en) 1999-08-17 2006-05-12 Treatment of metastatic disease

Publications (1)

Publication Number Publication Date
AU6784400A true AU6784400A (en) 2001-03-13

Family

ID=22529456

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67844/00A Abandoned AU6784400A (en) 1999-08-17 2000-08-17 Treatment of metastatic disease

Country Status (10)

Country Link
EP (2) EP1242060B1 (enExample)
JP (2) JP2003516930A (enExample)
AT (1) ATE324877T1 (enExample)
AU (1) AU6784400A (enExample)
CA (1) CA2380888A1 (enExample)
DE (1) DE60027768T2 (enExample)
DK (1) DK1242060T3 (enExample)
ES (1) ES2261230T3 (enExample)
PT (1) PT1242060E (enExample)
WO (1) WO2001012172A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
NZ521898A (en) 2000-03-31 2004-11-26 Purdue Research Foundation Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
EP1298221A1 (en) * 2001-09-28 2003-04-02 PrimaGen Holding B.V. Means and methods for treatment evaluation
EP1225233A3 (en) * 2001-01-23 2003-01-08 Amsterdam Support Diagnostics B.V. Means and methods for treatment evaluation
NZ537458A (en) * 2001-01-23 2007-02-23 Primagen Holding B Means and methods for treatment evaluation
ES2338305T3 (es) * 2001-09-28 2010-05-06 Purdue Research Foundation Metodo de tratamiento que utiliza conjugados ligando-inmunogeno.
JP2005535289A (ja) * 2002-02-15 2005-11-24 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １４１４分子、１４８１分子、１５５３分子、３４０２１分子、１７２０分子、１６８３分子、１５５２分子、１６８２分子、１６７５分子、１２８２５分子、９９５２分子、５８１６分子、１０００２分子、１６１１分子、１３７１分子、１４３２４分子、１２６分子、２７０分子、３１２分子、１６７分子、３２６分子、１８９２６分子、６７４７分子、１７９３分子、１７８４分子または２０４５分子を用いて、ａｉｄｓおよびｈｉｖ関連障害を処置するための方法および組成物
ATE525398T1 (de) * 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
JP2006501153A (ja) 2002-05-23 2006-01-12 パーデュー・リサーチ・ファウンデーション 診断及び治療用標的としての低分子量タンパク質チロシンホスファターゼ（ｌｍｗ−ｐｔｐ）
AU2004210463B2 (en) * 2003-02-07 2009-07-16 Ludwig Institute For Cancer Research Limited Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis
AU2003900541A0 (en) * 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
WO2004091375A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
US20050049176A1 (en) * 2003-04-11 2005-03-03 Kiener Peter A. EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
US8012681B2 (en) 2003-05-13 2011-09-06 Novartis Vaccines And Diagnostics, Inc. Methods of modulating metastasis and skeletal related events resulting from metastases
WO2005016381A2 (en) * 2003-07-21 2005-02-24 Medimmune, Inc. Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
CN1905899B (zh) * 2003-11-20 2011-09-28 医学免疫公司 EphA2激动性单克隆抗体及其使用方法
ES2321212T3 (es) 2004-05-18 2009-06-03 Alphavax, Inc. Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion.
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
KR101363252B1 (ko) 2005-02-04 2014-02-13 레이븐 바이오테크놀로지스, 인코퍼레이티드 Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
EA020324B1 (ru) 2006-07-18 2014-10-30 Санофи-Авентис АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
ES2517869T3 (es) 2006-09-12 2014-11-04 Alphavax, Inc. Partículas de replicones de alfavirus emparejadas con antígenos proteicos como adyuvantes inmunológicos
AU2007342333B2 (en) 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
CA2668417A1 (en) 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
SI2199390T1 (sl) 2007-08-30 2017-02-28 Daiichi Sankyo Company, Limited Proti-epha2 protitelo
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6729917B2 (ja) * 2016-08-19 2020-07-29 国立大学法人 東京大学 ＥｐｈＡ２ Ｎ末端フラグメント抗体
WO2020028749A1 (en) 2018-08-03 2020-02-06 Uab Research Foundation Methods and compositions for alphavirus vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2096417C (en) 1991-08-22 2000-10-10 Sarah S. Bacus Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
CA2103323A1 (en) * 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
ATE293989T1 (de) * 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten

Also Published As

Publication number Publication date
WO2001012172A1 (en) 2001-02-22
ES2261230T3 (es) 2006-11-16
ATE324877T1 (de) 2006-06-15
EP1242060A4 (en) 2003-09-24
WO2001012172B1 (en) 2001-08-16
JP2007306938A (ja) 2007-11-29
DE60027768D1 (de) 2006-06-08
EP2289940A3 (en) 2011-09-21
EP1242060A1 (en) 2002-09-25
CA2380888A1 (en) 2001-02-22
DK1242060T3 (da) 2006-08-21
EP2289940A2 (en) 2011-03-02
PT1242060E (pt) 2006-08-31
DE60027768T2 (de) 2007-04-05
EP1242060B1 (en) 2006-05-03
JP2003516930A (ja) 2003-05-20

Similar Documents

Publication Publication Date Title
US8591887B2 (en) EPHA2 as a therapeutic target for cancer
EP1242060B1 (en) Treatment of metastatic disease
AU2024219648A1 (en) Targeted therapy for small cell lung cancer
JP5601836B2 (ja) Ｔｅｓ７およびｔｅｓ７に結合する抗体
KR101960509B1 (ko) 클라우딘 6 특이적 항체
CN101155830B (zh) 结合epha2的抗体及其使用方法
JP2013039140A (ja) Ｓｍａｄ４欠損癌の増殖を阻害するための組成物および方法
US20090269340A1 (en) Antibodies to oncostatin m receptor
JP2007523834A (ja) 癌疾患修飾抗体
CN101432307A (zh) 显示cd44表面表达的细胞的细胞毒性介导
WO2003086456A2 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
AU2006202023B2 (en) Treatment of metastatic disease
EP1695702A2 (en) Treatment of metastatic disease
US20040048817A1 (en) Methods of immunotherapy and diagnosis
CA2459622C (en) Compositions and methods for restoring sensitivity to treatment with her2 antagonists
BRPI0901452A2 (pt) métodos para o tratamento de leucemia mielóide aguda
HK1133891A (en) Transferrin receptor antibodies

Legal Events

Date Code Title Description
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 20000817 TO 20001217 IN WHICH TO AMEND THE SPECIFICATION TO THE REQUIREMENTS OF REGULATION 1.5(1) IN ORDER TO COMPLY WITH SECTION 6(C) HAS BEEN LODGED

MK3 Application lapsed section 142(2)(c) - examination deferred under section 46 no request for examination
TH Corrigenda

Free format text: IN VOL 18, NO 3, PAGE(S) 73 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO PATENT APPLICATION'S 67843/00 AND 67844/00